# The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects

> **NCT07200596** · PHASE1 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 16 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** SHR-3045 Injection
- **DRUG:** SHR-3045 Placebo Injection

## Key facts

- **NCT ID:** NCT07200596
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-08
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07200596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07200596, "The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT07200596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*